Advertisement

Product › Details
AI-based drug discovery
![]() |
Next higher product group | drug discovery |
Atomwise, Inc.. (9/11/19). "Press Release: Atomwise Announces Largest China-US Collaboration for AI Drug Discovery". San Francisco, CA.
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules
Atomwise Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, today announced a collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.
“There is exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery,” said Dr. Abraham Heifets, CEO of Atomwise. “I am delighted to announce that Hansoh Pharma is our first partner in Asia. Hansoh Pharma is committed to innovation and shares our mission for global impact on patient health,” he added.
Scientific teams from Atomwise and Hansoh Pharma will collaborate closely on the programs. The combination of Atomwise’s AI technology and medicinal chemistry and protein structure expertise, and Hansoh Pharma’s fully integrated research and development, manufacturing and commercial capabilities has the potential to dramatically increase success and compress timelines for drug discovery and clinical development.
Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could reach US$1.5 billion.
About Atomwise
Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as over a hundred universities and hospitals in 19 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology. Learn more at atomwise.com or follow @AtomwiseInc.
Media Contact
Sara Dunn
SDunn@jpa.com
Record changed: 2022-03-09 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for AI-based drug discovery
- [1] Celeris Therapeutics GmbH. (2/24/22). "Press Release: CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors". Menlo Park, CA....
- [2] Gubra ApS. (2/10/22). "Press Release: Gubra ApS and Silence Therapeutics plc Collaborate to Develop RNAi Therapies against Novel Liver-directed Targets from Gubra’s streaMLine Platform". Hørsholm....
- [3] Celeris Therapeutics GmbH. (2/9/22). "Press Release: CelerisTx in Artificial Intelligence Research Collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled Degrader Discovery". Menlo Park, CA....
- [4] Celeris Therapeutics GmbH. (2/2/22). "Press Release: Celeris Therapeutics, the PIC Engineering Company, Announces the Appointment of Biotech Veterans to Lead Drug Discovery and Biology Efforts"....
- [5] Centogene N.V.. (1/20/22). "Press Release: Centogene Joins Forces with Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development". Cambridge, MA, Rostock & Berlin...
- [6] Exscientia plc. (1/7/22). "Press Release: Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines". Paris, Oxford & Boston, MA....
- [7] Signia Therapeutics S.A.S.. (1/5/22). "Press Release: Signia Therapeutics Receives a €1.7 Million Deeptech Development Grant from Bpifrance". Lyon....
- [8] Deep Pharma Intelligence Ltd.. (12/2021). Report: AI for Drug Discovery, Biomarker. Development and Advanced R&D Landscape Overview Q4 2021. [https://www.deep-pharma.tech, 12/29/21]...
- [9] Recursion Pharmaceuticals, Inc.. (12/7/21). "Press Release: Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening...
- [10] Recursion Pharmaceuticals, Inc.. (12/6/21). "Press Release: Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities". Salt Lake City, UT....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top